Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990–2007

Abstract During the period March 1, 1998 to January 14, 2007, approximately 6 million doses of Anthrax vaccine adsorbed (AVA) vaccine were administered. As of January 16, 2007, 4753 reports of adverse events following receipt of AVA vaccination had been submitted to the Vaccine Adverse Event Reporti...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2009-01, Vol.27 (2), p.290-297
Main Authors: Niu, Manette T, Ball, Robert, Woo, Emily Jane, Burwen, Dale R, Knippen, Maureen, Braun, M. Miles
Format: Article
Language:English
Subjects:
Adult
Adverse Drug Reaction Reporting Systems - statistics & numerical data
Allergy and Immunology
Aluminum
Anthrax
Anthrax - prevention & control
Anthrax vaccine
Anthrax Vaccines - adverse effects
Applied microbiology
Arthritis
Bacteriology
Bayes Theorem
Biological and medical sciences
Cardiac arrhythmia
Data mining
Diabetes
Drug-Related Side Effects and Adverse Reactions
Female
Fundamental and applied biological sciences. Psychology
Guillain-Barre syndrome
Humans
Illnesses
Immunization
Male
Microbiology
Middle Aged
Miscellaneous
Post-marketing surveillance
Product Surveillance, Postmarketing
Software
United States
Vaccination - adverse effects
Vaccines
Vaccines - adverse effects
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
VAERS
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract During the period March 1, 1998 to January 14, 2007, approximately 6 million doses of Anthrax vaccine adsorbed (AVA) vaccine were administered. As of January 16, 2007, 4753 reports of adverse events following receipt of AVA vaccination had been submitted to the Vaccine Adverse Event Reporting System (VAERS). Taken together, reports to VAERS did not definitively link any serious unexpected risk to this vaccine, and review of death and serious reports did not show a distinctive pattern indicative of a causal relationship to AVA vaccination. Continued monitoring of VAERS and analysis of potential associations between AVA vaccination and rare, serious events is warranted.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.10.044